Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry

AIM: Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therapy. Safety data for this switching are urgently ne...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Beyer-Westendorf, Jan, Gelbricht, Vera, Förster, Kati, Ebertz, Franziska, Röllig, Denise, Schreier, Thomas, Tittl, Luise, Thieme, Christoph, Hänsel, Ulrike, Köhler, Christina, Werth, Sebastian, Kuhlisch, Eberhard, Stange, Thoralf, Röder, Ingolf, Weiss, Norbert
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Drug Safety
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239984/
https://ncbi.nlm.nih.gov/pubmed/24697922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12391
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados